scholarly journals Effect of Dementia on the Use of Drugs for Secondary Prevention of Ischemic Heart Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Nicole R. Fowler ◽  
Amber E. Barnato ◽  
Howard B. Degenholtz ◽  
Angela M. Curcio ◽  
James T. Becker ◽  
...  
Keyword(s):  
Heart Disease ◽  
Secondary Prevention ◽  
Ischemic Heart Disease ◽  
Cardiovascular Health ◽  
Beta Blockers ◽  
Ischemic Heart ◽  
Lipid Lowering ◽  
Health Study ◽  
Cardiovascular Health Study ◽  
Converting Enzyme Inhibitors

Background. Dementia and cardiovascular disease (CVD) are frequently comorbid. The presence of dementia may have an effect on how CVD is treated.Objective. To examine the effect of dementia on the use of four medications recommended for secondary prevention of ischemic heart disease (IHD): angiotensin-converting enzyme inhibitors, beta-blockers, lipid-lowering medications, and antiplatelet medications.Design. Retrospective analysis of data from the Cardiovascular Health Study: Cognition Study.Setting and Subjects. 1,087 older adults in four US states who had or developed IHD between 1989 and 1998.Methods. Generalized estimating equations to explore the association between dementia and the use of guideline-recommended medications for the secondary prevention of IHD.Results. The length of follow-up for the cohort was 8.7 years and 265 (24%) had or developed dementia during the study. Use of medications for the secondary prevention of IHD for patients with and without dementia increased during the study period. In models, subjects with dementia were not less likely to use any one particular class of medication but were less likely to use two or more classes of medications as a group (OR, 0.60; 95% CI, 0.36–0.99).Conclusions. Subjects with dementia used fewer guideline-recommended medications for the secondary prevention of IHD than those without dementia.

scholarly journals Studies of the outcome of the treatment with beta-blockers in secondary prevention of the ischemic heart disease

2009 ◽  
Vol 62 (9-10) ◽  
pp. 450-455 ◽  
Author(s):  
Vesna Radovic
Keyword(s):  
Myocardial Infarction ◽  
Heart Disease ◽  
Angina Pectoris ◽  
Secondary Prevention ◽  
Ischemic Heart Disease ◽  
Beta Blockers ◽  
Convincing Evidence ◽  
Ischemic Heart ◽  
Necessary Condition ◽  
Professional Literature

Convincing evidence of the decline of mortality has been achieved with beta-blockers in patients with an acute myocardial infarction and in post-infarction follow-up. The beta-blockers are also the most efficient antianginal medications for the decrease of ischemia in outpatients. They are highly efficient as a monotherapy for angina and are also a medication of choice for angina after the coronary. The objective of this work was an estimate of the use of beta-blockers in secondary prevention of the ischemic heart disease and eliminating doubts concerning their prescription. The method of the analysis sums up the results of a twenty-five- year study on of the outcome of the treatment with beta-blockers in secondary prevention of the ischemic heart disease. The method of the work implies an examination of the professional literature and the data-bases, such as MEDLINE, PubMed and KOBSON. The first studies concerned non-selective beta-blockers, used orally. The following studies concerned cardioselective beta-blockers, metoprolol and atenolol. Several studies followed also the effect of beta-blockers and heparin, or beta-blockers and antagonists of calcium towards placebo, in patients with an unstable angina pectoris. Beta-blockers are an essential drug in secondary prevention of the myocardial infarction and in chronic heart failure. The necessary condition for the efficiency of beta-blockers is an early use. Beta-blockers should be given within 12 hours after the appearance of pain. The continuation of the therapy with beta-blockers after the acute phase is considered to be important in the decrease of the infarction zone expansion. Prophylactic use of beta-blockers after the coronary has an excellent effect, above all in patients with a minor, uncomplicated coronary. Though certain groups of beta-blockers have some special characteristics, when it comes to the treatment of angina pectoris, all beta-blockers are efficient. Generally, patients react well to them. Preference is given to cardioselective remedies, in patients with diabetes or lung disease. Exhaustive controlled clinical studies affirm beta-blockers as drugs that reduce mortality in secondary prevention of the ischemic heart disease.

scholarly journals A Cross-Sectional Study To Evaluate age and Gender Related Differences in Drug Utilization in Ischemic Heart Disease at a Tertiary Care Hospital

2018 ◽  
Vol 11 (4) ◽  
pp. 1967-1974
Author(s):  
Praveen Panchaksharimath ◽  
A. N. Praveen ◽  
R. Manjunath
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Drug Utilization ◽  
Ischemic Heart ◽  
Lipid Lowering ◽  
Prescription Data ◽  
Cross Sectional ◽  
Age And Gender ◽  
Anti Platelet Therapy ◽  
And Gender

Drug utilization study is a powerful exploratory tool to evaluate the present trends of drug prescribing and appropriateness of prescription. To analyse the age and gender related differences in utilization of different classes of drugs in patients for Ischemic heart disease (IHD) management. This cross-sectional observational study was conducted from August 2017 to March 2018 in Cardiology department, PMSSY, BMC&RI, Bengaluru. The demographic, and drug prescription data of IHD patients were analyzed according to age group (18–59 years versus ≥ 60 years) and gender wise. Out of 520 patients diagnosed with IHD, 68% were male patients and 60% were aged ≥ 60 years. The most common co-morbid condition was Hypertension (66%) and was significant in patients aged ≥ 60 years (P= 0.0033). Anti-platelet drugs (100%) followed by Lipid lowering drugs (96%) were most commonly prescribed. The average number of drugs per prescription was found to be 6.44. Prescription of Dual anti-platelet therapy was found to be significant among men (<0.0001). Prescription of Diuretics (p = 0.045) and Pregabalin (p = 0.031) were significantly higher among females and Prescription of Angiotensin receptor blockers (ARBs) was significantly higher among those aged 18–59 years. Hypertension and Diabetes Mellitus were the most common co-morbidities observed with IHD. ARBs, Diuretics, Proton pump inhibitors, Anti Diabetic Agents and Pregabalin showed significant differences in the drug utilization with respect to age and gender. Dual anti-platelet therapy was observed to be significantly higher among males. This study has been registered in CTRI (CTRI/2018/05/013949).

scholarly journals Unique referral system contributes to long-term net clinical benefits in patients undergoing secondary prevention therapy after percutaneous coronary intervention

PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0242707
Author(s):  
Shigetaka Kageyama ◽  
Koichiro Murata ◽  
Ryuzo Nawada ◽  
Tomoya Onodera ◽  
Yuichiro Maekawa
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Heart Disease ◽  
Secondary Prevention ◽  
Ischemic Heart Disease ◽  
Coronary Intervention ◽  
Ischemic Heart ◽  
Referral System ◽  
Clinical Events ◽  
Percutaneous Coronary ◽  
Clinical Benefits

Cardiovascular disease, including ischemic heart disease, is a leading cause of death worldwide. Improvement of the secondary prevention of ischemic heart disease is necessary. We established a unique referral system to connect hospitals and outpatient clinics to coordinate care between general practitioners and cardiologists. Here, we evaluated the impact and long-term benefits of our system for ischemic heart disease patients undergoing secondary prevention therapy after percutaneous coronary intervention. This single-center retrospective observational study included 3658 consecutive patients who underwent percutaneous coronary intervention at Shizuoka City Hospital between 2010 and 2019. After percutaneous coronary intervention, patients were considered conventional outpatients (conventional follow-up group) or subjected to our unique referral system (referral system group) at the attending cardiologist’s discretion. To audit compliance of the treatment with the latest Japanese guidelines, we adopted a circulation-type referral system, whereby general practitioners needed to refer registered patients at least once a year, even if no cardiac events occurred. Clinical events in each patient were evaluated. Net adverse clinical events were defined as a combination of major adverse cardiac, cerebrovascular, and major bleeding events. There were 2241 and 1417 patients in the conventional follow-up and referral system groups, with mean follow-ups of 1255 and 1548 days and cumulative net adverse clinical event incidences of 27.6% and 21.5%, respectively. Kaplan–Meier analysis showed that the occurrence of net adverse clinical events was significantly lower in the referral system group than in the conventional follow-up group (log-rank: P<0.001). Univariate and multivariate analyses revealed that the unique referral system was a significant predictor of the net clinical benefits (hazard ratio: 0.56, 95% confidence interval: 0.37–0.83, P = 0.004). This result was consistent after propensity-score matching. In summary, our unique referral system contributed to long-term net clinical benefits for the secondary prevention of ischemic heart disease after percutaneous coronary intervention.

scholarly journals The prediction model for cardiovascular disease using Yazd's health study data (YaHS)

2019 ◽  
Author(s):  
Seyed MohammadReza Tabatabaei Nodoushan1 ◽  
Fatemeh Saadatjoo ◽  
Masoud Mirzaei
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Cost Effective ◽  
Mortality Rates ◽  
Study Data ◽  
Ischemic Heart ◽  
Health Study ◽  
Screening Methods ◽  
The People ◽  
Health And Disease

Introdution: Ischemic heart disease is one of the most common diseases, which has led to high mortality rates all over the world. This disease is caused by narrowing or blockage of coronary arteries, which are the provider of blood to the heart. Identifying the people susceptible to this disease and bringing changes in their lifestyles has been said to reduce the related mortality rates and increase the patient's longevity. Methods: Yazd people Health Study (YaHS) was conducted on a random sample of 10,000 people living in the city of Yazd, Iran in the years 2014-15 for a general health and disease survey. These data were first balanced by bootstrapping technique due to their unbalanced nature. Next, classification methods were used in the training phase. Various classifiers, such as artificial neural network, rule inducer, regression, and AdaBoost were used in order to evaluate the proposed method with two scenarios. Results: The results showed that the screening of the people susceptible to ischemic heart disease had the most significant effect on increasing the sensitivity of the discovery classifier of CN2 subgroup through using balanced data by bootstrapping method followed by their analysis for the purpose of producing a sample of the patients. This classifier proved to have the potential for detecting 83.6% of the people susceptible to this disease. Conclusion: Therefore, it can be concluded that data mining methods are effective in screening for susceptible people with ischemic heart disease. This method can be compared with other traditional screening methods in that it is more cost-effective and faster.

Treatment of ischemic heart disease in women during the pathological menopause

1982 ◽  
Vol 63 (3) ◽  
pp. 15-17
Author(s):  
E. V. Tsybulina ◽  
L. A. Emelyanova
Keyword(s):  
Coronary Artery Disease ◽  
Heart Disease ◽  
Comparative Analysis ◽  
Coronary Artery ◽  
Ischemic Heart Disease ◽  
Beta Blockers ◽  
Ischemic Heart ◽  
Myocardial Dystrophy ◽  
Artery Disease ◽  
Antianginal Drugs

A comparative analysis of the effectiveness of antianginal drugs (papaverine, persantine, intensain, nitrong, anaprilin) in combination with climacteric myocardial dystrophy in women was carried out. The data obtained make it possible to recommend beta-blockers (anaprilin, obzidan) for the treatment of coronary artery disease in women against the background of pathological menopause for wider use.

Sign in / Sign up

Export Citation Format

Share Document